These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554 [TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit. El-Mekkawy MS; Saleh NY; Sonbol AA Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717 [TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients. Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031 [TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. Savva A; Raftogiannis M; Baziaka F; Routsi C; Antonopoulou A; Koutoukas P; Tsaganos T; Kotanidou A; Apostolidou E; Giamarellos-Bourboulis EJ; Dimopoulos G J Infect; 2011 Nov; 63(5):344-50. PubMed ID: 21839112 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Backes Y; van der Sluijs KF; Mackie DP; Tacke F; Koch A; Tenhunen JJ; Schultz MJ Intensive Care Med; 2012 Sep; 38(9):1418-28. PubMed ID: 22706919 [TBL] [Abstract][Full Text] [Related]
8. Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. Zeng M; Chang M; Zheng H; Li B; Chen Y; He W; Huang C Am J Emerg Med; 2016 Mar; 34(3):375-80. PubMed ID: 26615223 [TBL] [Abstract][Full Text] [Related]
9. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J; Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800 [TBL] [Abstract][Full Text] [Related]
10. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review. Velissaris D; Pierrakos C; Karamouzos V; Pantzaris ND; Gogos C Acta Clin Belg; 2021 Feb; 76(1):79-84. PubMed ID: 31434557 [No Abstract] [Full Text] [Related]
11. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Casagranda I; Vendramin C; Callegari T; Vidali M; Calabresi A; Ferrandu G; Cervellin G; Cavazza M; Lippi G; Zanotti I; Negro S; Rocchetti A; Arfini C Intern Emerg Med; 2015 Sep; 10(6):725-30. PubMed ID: 26156446 [TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries. Patrani M; Tsaganos T; Kotzampassi K; Paraschos M; Katsenos C; Giamarellos-Bourboulis EJ; Mandragos K Biomarkers; 2016 Nov; 21(7):660-4. PubMed ID: 27121128 [TBL] [Abstract][Full Text] [Related]
14. The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Wrotek A; Jackowska T Respir Physiol Neurobiol; 2015 Apr; 209():120-3. PubMed ID: 25602915 [TBL] [Abstract][Full Text] [Related]
15. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968 [TBL] [Abstract][Full Text] [Related]
16. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033 [TBL] [Abstract][Full Text] [Related]
17. Risk stratification and triage in the emergency department: has this become 'suPAR' easy? Koch A; Tacke F J Intern Med; 2012 Sep; 272(3):243-6. PubMed ID: 22759240 [No Abstract] [Full Text] [Related]
18. Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness. Cyrille NB; Villablanca PA; Ramakrishna H Ann Card Anaesth; 2016; 19(2):214-6. PubMed ID: 27052059 [TBL] [Abstract][Full Text] [Related]